← Search & browse all drugs
DERMATOLOGICALS › ANTIPSORIATICS › ANTIPSORIATICS FOR TOPICAL USE › Other antipsoriatics for topical use
tazarotene and ulobetasol
D05AX55
Forms & Strengths
- Topical lotion: tazarotene 0.045% / ulobetasol propionate 0.01%
Adult Dosing
- Apply a thin layer to affected areas of plaque psoriasis once daily for up to 8 weeks
- Discontinue when control is achieved
- Maximum weekly dose should not exceed 50 grams
Pediatric Dosing
- Safety and efficacy in pediatric patients under 18 years have not been established
Indications
- Topical treatment of plaque psoriasis in adults
Mechanism of Action
- Tazarotene is a retinoid prodrug converted to tazarotenic acid, modulating gene expression, cellular differentiation, and proliferation
- Ulobetasol propionate is a high-potency corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties
Contraindications
- Pregnancy
- Known hypersensitivity to tazarotene, ulobetasol, or any component of the formulation
- Most viral, fungal, or tubercular skin lesions
- Rosacea and perioral dermatitis
Adverse Reactions
- Contact dermatitis
- Application site pain, irritation, and pruritus
- Skin atrophy, striae, and telangiectasia
- Hypopigmentation
- HPA axis suppression
Drug Interactions
- Concomitant use of other potentially irritating topical products may increase skin irritation
- Drugs with known photosensitizing potential may additive-ly increase risk of phototoxicity
- Systemic corticosteroids or potent CYP3A4 inhibitors may potentiate systemic corticosteroid effects
Curated Content: Needs Vetting Before Put to Clinical Use